OMB APPROVAL |
||
OMB Number: 3235-0145 |
||
Expires: December 31, 2005 |
||
Estimated average burden hours per response...11 |
||
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
þ Rule 13d-1(c)
o Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
CUSIP No. |
371916107 |
Page | 2 |
of | 5 |
1 | NAMES OF REPORTING PERSONS: Merck & Co., Inc. |
||||
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): | |||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): |
||||
(a) o | |||||
(b) o | |||||
3 | SEC USE ONLY: | ||||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION: | ||||
New Jersey | |||||
5 | SOLE VOTING POWER: | ||||
NUMBER OF | 1,687,500 | ||||
SHARES | 6 | SHARED VOTING POWER: | |||
BENEFICIALLY | |||||
OWNED BY | |||||
EACH | 7 | SOLE DISPOSITIVE POWER: | |||
REPORTING | |||||
PERSON | 1,687,500 | ||||
WITH: | 8 | SHARED DISPOSITIVE POWER: | |||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: | ||||
1,687,500 | |||||
10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): | ||||
o | |||||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): | ||||
5.64% | |||||
12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): | ||||
CO |
(a) | Name of Issuer: | ||
Inovio Biomedical Corp. | |||
(b) | Address of Issuers Principal Executive Offices: | ||
11494 Sorrento Valley Road San Diego, California 92121-1318 |
(a) | Name of Person Filing: | ||
Merck & Co., Inc. | |||
(b) | Address of Principal Business Office or, if none, Residence: | ||
One Merck Drive, Whitehouse Station, NJ 08889 |
|||
(c) | Citizenship: | ||
NJ | |||
(d) | Title of Class of Securities: | ||
Common Stock, par value $0.001 | |||
(e) | CUSIP Number: | ||
371916107 |
(a) | Amount beneficially owned: 1,687,500. | ||
(b) | Percent of class: 5.64%. | ||
(c) | Number of shares as to which the person has: |
(i) | Sole power to vote or to direct the vote 1,687,500. | ||
(ii) | Shared power to vote or to direct the vote . | ||
(iii) | Sole power to dispose or to direct the disposition of 1,687,500. | ||
(iv) | Shared power to dispose or to direct the disposition of . |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
January 9, 2006 | ||
Date | ||
/s/ Celia A. Colbert | ||
Signature | ||
Celia A. Colbert Vice President, Secretary and Assistant General Counsel |
||
Name/Title |